Janux plunges after early-stage data for prostate cancer drug

Shares of drug developer Janux Therapeutics JANX.O fall 44% to $18.99 premarket

Co says early-stage trial of JANX007 in advanced prostate cancer met main goals with durable responses and manageable safety

Shares drop as results aligned with analyst expectations but fell short of lofty buyside hopes, says brokerage BTIG

JANX says men with advanced prostate cancer saw disease remain stable for about 8–9 months on JANX007

In chemo-naive patients, drug led to rapid and significant declines in prostate-specific antigen, a key cancer marker

Up to last close, stock down ~37% YTD